Home>Topics>Companies>Novo Nordisk

Novo Nordisk

  1. All
  2. Commentary
  3. Video Reports
  4. Headlines
  1. UPDATE 2- Novo launches Saxenda in US, sees more launches in 2015

    Headlines

    Wed, 22 Apr 2015

    COPENHAGEN, April 22 (Reuters) - Novo Nordisk has launched its Saxenda obesity drug in the United States, it said on Wednesday, a long-awaited milestone that will provide a new revenue stream for the Danish drugmaker.

  2. Novo Nordisk says Saxenda obesity drug to cost $1,068 per month

    Headlines

    Wed, 22 Apr 2015

    COPENHAGEN, April 22 (Reuters) - Novo Nordisk 's new obesity drug Saxenda, which has been launched in the United States on Wednesday, will cost $1,068 per month in the country, the company told Reuters in an email on Wednesday.

  3. Novo Nordisk launches Saxenda obesity drug in United States

    Headlines

    Wed, 22 Apr 2015

    COPENHAGEN, April 22 (Reuters) - Novo Nordisk said on Wednesday it had launched its Saxenda obesity drug in the United States, a long-awaited milestone that will provide a new revenue stream for the Danish drugmaker.

  4. BRIEF- Novo Nordisk - reduction in share capital by the cancellation of treasury shares

    Headlines

    Wed, 22 Apr 2015

    COPENHAGEN, April 22 (Reuters) - Novo Nordisk A/S : * Reduction in share capital by the cancellation of treasury shares * Volume will be reduced by 50,000,000 shares to 2,062,564,000 shares

  5. MOVES-Bjarne Graven Larsen appointed CFO of Novo A/S

    Headlines

    Mon, 13 Apr 2015

    COPENHAGEN, April 13 (Reuters) - Bjarne Graven Larsen has been appointed financial chief at holding company Novo A/S, majority shareholder in Danish insulin maker Novo Nordisk and enzyme maker Novozymes.

  6. Novo Nordisk opens new insulin factory in Russia

    Headlines

    Fri, 10 Apr 2015

    COPENHAGEN, April 10 (Reuters) - Denmark's Novo Nordisk said on Friday it had opened a factory in Kaluga, Russia, for the production and assembly of insulin cartridges and pre-filled injection pens used for the treatment of diabetes.

  7. UPDATE 1-FDA accepts Novo Nordisk's resubmitted application for insulin drug

    Headlines

    Tue, 7 Apr 2015

    April 7 (Reuters) - Denmark's Novo Nordisk A/S said the U.S. Food and Drug Administration accepted a resubmitted application for its key insulin drug, Tresiba, based on interim analysis data from a...

  8. FDA accepts Novo Nordisk's resubmitted application for insulin drug

    Headlines

    Tue, 7 Apr 2015

    April 7 (Reuters) - Denmark's Novo Nordisk said the U.S. Food and Drug Administration accepted a resubmitted application for its insulin drug, Tresiba.

  9. European shares post 2015's biggest weekly fall despite Novo Nordisk surge

    Headlines

    Fri, 27 Mar 2015

    * FTSEurofirst 300 up 0.2 pct after losing 1.9 pct in two days

  10. European shares set for 2015's biggest weekly fall despite Novo Nordisk surge

    Headlines

    Fri, 27 Mar 2015

    * Euro zone shares recover as euro falls back (Recasts, adds quotes)

« Prev12345Next »
Content Partners